Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01578564 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
A Phase 1 study of Cancer, sponsored by Soricimed Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 3
- Study locations
NCT01578564: Completed Phase 1 study of Cancer, sponsored by Soricimed Biopharma.
NCT01578564 is a Phase 1 study of Cancer that has completed, run by Soricimed Biopharma. The registered enrollment target is 23 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01578564, a Phase 1 study of Cancer, has completed, sponsored by Soricimed Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of the drug SOR-C13 when given as an intravenous infusion in patients with ovarian cancer or other cancers known to over express the TRPV6 calcium channel.
Conditions Studied
Interventions
- DRUG SOR-C13
Study Locations (3)
Ontario
- Juravinski Cancer Center - Hamilton
- London Health Sciences Centre - London
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01578564
The ClinicalTrials.gov registry entry for NCT01578564 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Soricimed Biopharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which SOR-C13 is the first listed.
NCT01578564 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ontario, Texas.
Frequently Asked Questions
What is clinical trial NCT01578564 about?
NCT01578564 is a clinical study titled "Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel". The purpose of this study is to determine the safety and tolerability of the drug SOR-C13 when given as an intravenous infusion in patients with ovarian cancer or other cancers known to over express the TRPV6 calcium channel.
What is the current status of trial NCT01578564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2012-07. Estimated completion is 2016-03.
What conditions does trial NCT01578564 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01578564?
The interventions under investigation include: SOR-C13 (DRUG).
Who is sponsoring clinical trial NCT01578564?
This trial is sponsored by Soricimed Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01578564 being conducted?
This trial has 3 study locations across Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.